盐酸羟考酮片剂说明
制造商：
辉瑞公司实验室
类药物：
阿片类药物。
活性成分（S）：
羟考酮盐酸5毫克，7.5mg;标签。
指示（S）：
对于急性和慢性中度至重度疼痛，阿片类镇痛药的使用是适当的管理。
药理作用：
羟考酮盐酸是一个纯粹的阿片受体激动剂和相对万亩受体的选择性，但它可以与其他阿片受体相互作用，在高剂量。羟考酮的主要治疗作用是镇痛。
法律分类：
中基
成人：
吞下。个性化。 ≥0-18岁：阿片类药物初治：最初5 - 15毫克每4-6小时。从其他阿片类药物或组合的转换：见文献。
儿童：
<18yrs：不推荐。
禁忌症（S）：
呼吸抑制（在不受监督的设置，或在复苏设备的情况下）。麻痹性肠梗阻。急性或严重支气管哮喘或高碳酸血症。
警告/注意事项：
肾或肝功能损害。慢性阻塞性肺病。肺心病。严重脊柱侧后凸。中枢神经系统抑制。昏迷。头部受伤。颅内压增高。循环性休克。癫痫症。肾上腺皮质功能不全（如阿狄森氏病）。震颤性谵妄。中毒性精神病。甲状腺功能减退。低血容量。胃肠道或顾梗阻。急性腹痛的条件。胆道疾病。急性胰腺炎。吸毒者。急性酒精中毒。避免突然停止。老人。虚弱。怀孕（Cat.B）。监视器的新生儿，其母亲已采取羟考酮，呼吸抑制的迹象。劳动和分娩，哺乳母亲：不推荐。
互动（补）：
在14天的单胺氧化抑制剂：不建议。避免伴随酒精或含有酒精的药物。添加剂中枢神经系统抑制，低血压与其他中枢神经系统抑制剂（例如，一般的麻醉剂，止吐药，吩噻嗪，苯二氮卓类药物，镇静剂，镇静剂，安眠药，酒精等），考虑减少剂量。会增强骨骼肌松弛神经肌肉阻断作用。伴随混合激动剂/拮抗剂（布托啡诺，纳布啡，喷他佐辛），部分激动剂（如丁丙诺啡）：不推荐。可能可以通过CYP3A4抑制剂（如伏立康唑，红霉素，酮康唑，利托那韦）。可拮抗由CYP3A4诱导剂（如利福平，卡马西平，苯妥英）。注意与抗胆碱药;尿潴留和/或严重便秘的风险增加。
不良反应（S）：
恶心，便秘，呕吐，头痛，皮肤瘙痒，失眠多梦，头晕，乏力，嗜睡，呼吸抑制，低血压。
如何提供：
标签-100
最后更新：
2012年2月8日
Manufacturer:
Pfizer Labs
Pharmacological Class:
Opioid.
Active Ingredient(s):
Oxycodone HCl 5mg, 7.5mg; tabs.
Indication(s):
For the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Pharmacology:
Oxycodone HCl is a pure opioid agonist and is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia.
Legal Classification:
CII
Adults:
Swallow whole. Individualize. ≥18yrs: Opioid-naïve: initially 5–15mg every 4–6 hours as needed. Converting from other opioids or combinations: see literature.
Children:
<18yrs: not recommended.
Contraindication(s):
Respiratory depression (in unmonitored settings or in the absence of resuscitative equipment). Paralytic ileus. Acute or severe bronchial asthma or hypercarbia.
Warnings/Precautions:
Renal or hepatic impairment. COPD. Cor pulmonale. Severe kyphoscoliosis. CNS depression. Coma. Head injury. Increased intracranial pressure. Circulatory shock. Seizure disorders. Adrenocortical insufficiency (eg, Addison's disease). Delirium tremens. Toxic psychosis. Hypothyroidism. Hypovolemia. GI or GU obstruction. Acute abdominal conditions. Biliary tract disease. Acute pancreatitis. Drug abusers. Acute alcoholism. Avoid abrupt cessation. Elderly. Debilitated. Pregnancy (Cat.B). Monitor neonates, whose mothers have been taking oxycodone, for signs of respiratory depression. Labor & delivery, nursing mothers: not recommended.
Interaction(s):
Within 14 days of MAOIs: not recommended. Avoid concomitant alcohol or alcohol-containing medications. Additive CNS depression, hypotension with other CNS depressants (eg, general anesthetics, antiemetics, phenothiazines, benzodiazepines, other tranquilizers, sedatives, hypnotics, alcohol); consider reducing dose. May potentiate the neuromuscular blocking action of skeletal muscle relaxants. Concomitant mixed agonists/antagonists, (butorphanol, nalbuphine, pentazocine), partial agonists (eg, buprenorphine): not recommended. May be potentiated by CYP3A4 inhibitors (eg, voriconazole, erythromycin, ketoconazole, ritonavir). May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). Caution with anticholinergics; increased risk of urinary retention and/or severe constipation.
Adverse Reaction(s):
Nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, somnolence; respiratory depression, hypotension.
How Supplied:
Tabs—100
Last Updated:
2/8/2012